Akero Therapeutics, Inc. (AKRO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Andrew Cheng M.D., Ph.D. | President, CEO & Director | 1.04M | 15.28M | 1967 |
| Dr. Jonathan M. Young J.D., Ph.D. | Co-Founder, Executive VP, COO & Secretary | 672.35k | 584.34k | 1970 |
| Dr. Timothy Rolph | Co-Founder & Chief Scientific Officer | 722.32k | 2.16M | 1954 |
| Mr. William R. White J.D. | Executive VP, CFO, Treasurer & Head of Corporate Development | 678.06k | 839.84k | 1973 |
| Ms. Catriona Yale | Executive VP & Chief Development Officer | 678.06k | 458.9k | 1972 |
| Mr. Scott A. Gangloff | Chief Technical Officer | -- | -- | 1974 |
| Mr. David West J.D. | Vice President of Legal | -- | -- | -- |
| Mr. John J. Schembri | Vice President & Head of Finance | -- | -- | 1962 |
| Mr. Patrick Lamy | Senior Vice President of Commercial Strategy | -- | -- | 1973 |
Akero Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 58
Description
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Corporate Governance
Upcoming Events
August 9, 2024 at 12:30 PM UTC - August 13, 2024 at 12:30 PM UTC
Akero Therapeutics, Inc. Earnings Date